Harlan S. Robins net worth and biography

Harlan Robins Biography and Net Worth

Dr. Harlan Robins is the co-founder and Chief Scientific Officer of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Prior to co-founding Adaptive, Harlan served in various roles in the Computational Biology Program at Fred Hutch, including as an Assistant Faculty Member from 2006 to 2011, as an Associate from 2011 to April 2016, and as a Full Member and the Head of the program from April 2016 to June 2019. Harlan holds a BS in Physics from Harvard University and a master’s degree and PhD in Physics from the University of California, Berkeley, with a visiting appointment to the California Institute of Technology. Harlan received postdoctoral appointments in the particle theory group at the Weizmann Institute of Science in Israel and at the Institute for Advanced Study in Princeton, NJ.

What is Harlan S. Robins' net worth?: The estimated net worth of Harlan S. Robins is at least $468,099.45 as of August 27th, 2021. Dr. Robins owns 73,255 shares of Adaptive Biotechnologies stock worth more than $468,099 as of December 21st. This net worth approximation does not reflect any other investments that Dr. Robins may own. Additionally, Dr. Robins receives an annual salary of $711,090.00 as Insider at Adaptive Biotechnologies. Learn More about Harlan S. Robins' net worth.
How old is Harlan S. Robins?: Dr. Robins is currently 51 years old. There are 6 older executives and no younger executives at Adaptive Biotechnologies. The oldest executive at Adaptive Biotechnologies is Ms. Stacy L. Taylor, Senior VP, General Counsel & Corporate Secretary, who is 64 years old. Learn More on Harlan S. Robins' age.
What is Harlan S. Robins' salary?: As the Insider of Adaptive Biotechnologies Co., Dr. Robins earns $711,090.00 per year. There are 2 executives that earn more than Dr. Robins. The highest earning executive at Adaptive Biotechnologies is Mr. Chad M. Robins M.B.A., Co-Founder, CEO & Chairman, who commands a salary of $1,000,000.00 per year. Learn More on Harlan S. Robins' salary.
How do I contact Harlan S. Robins?: The corporate mailing address for Dr. Robins and other Adaptive Biotechnologies executives is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. Adaptive Biotechnologies can also be reached via phone at (206) 659-0067 and via email at [email protected]. Learn More on Harlan S. Robins' contact information.
Has Harlan S. Robins been buying or selling shares of Adaptive Biotechnologies?: Harlan S. Robins has not been actively trading shares of Adaptive Biotechnologies during the last quarter. Most recently, Harlan S. Robins sold 300 shares of the business's stock in a transaction on Thursday, November 18th. The shares were sold at an average price of $31.36, for a transaction totalling $9,408.00. Learn More on Harlan S. Robins' trading history.
Who are Adaptive Biotechnologies' active insiders?: Adaptive Biotechnologies' insider roster includes R. Adams (COO), Lance Baldo (Insider), Sharon Benzeno (Insider), Chad Cohen (CFO), Egon Durban (Director), David Goel (Director), Michelle Griffin (Director), Francis Lo (Insider), Jyoti Palaniappan (SVP), Chad Robins (CEO), Chad Robins (CEO), Harlan Robins (Insider), Julie Rubinstein (President), and Stacy Taylor (SVP). Learn More on Adaptive Biotechnologies' active insiders.
Are insiders buying or selling shares of Adaptive Biotechnologies?: During the last twelve months, insiders at the sold shares 6 times. They sold a total of 124,555 shares worth more than $429,325.41. The most recent insider tranaction occured on November, 18th when CFO Kyle Piskel sold 248 shares worth more than $1,235.04. Insiders at Adaptive Biotechnologies own 6.2% of the company. Learn More about insider trades at Adaptive Biotechnologies.
Information on this page was last updated on 11/18/2024.

Harlan S. Robins Insider Trading History at Adaptive Biotechnologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/18/2021	Sell	300	$31.36	$9,408.00
10/21/2021	Sell	3,700	$33.73	$124,801.00
10/19/2021	Sell	3,800	$33.69	$128,022.00
10/8/2021	Sell	3,895	$32.96	$128,379.20
10/6/2021	Sell	3,895	$32.27	$125,691.65
9/14/2021	Sell	3,895	$36.74	$143,102.30	73,255
8/27/2021	Sell	3,895	$34.78	$135,468.10	73,255
8/25/2021	Sell	3,895	$34.09	$132,780.55
7/21/2021	Sell	3,895	$37.82	$147,308.90	73,255
7/19/2021	Sell	3,895	$37.12	$144,582.40	73,255
6/11/2021	Sell	3,895	$38.41	$149,606.95	73,255
6/9/2021	Sell	3,895	$35.99	$140,181.05	73,255
5/6/2021	Sell	3,895	$35.70	$139,051.50	73,255
5/4/2021	Sell	3,895	$36.14	$140,765.30	73,255
4/22/2021	Sell	7,790	$43.18	$336,372.20	81,045
4/20/2021	Sell	11,685	$40.52	$473,476.20	81,045
3/25/2021	Sell	5,290	$38.30	$202,607.00	77,150
3/23/2021	Sell	7,790	$41.93	$326,634.70	77,150
2/3/2021	Sell	7,790	$59.58	$464,128.20	8,469
2/1/2021	Sell	7,790	$55.83	$434,915.70	8,469
1/21/2021	Sell	23,370	$66.82	$1,561,583.40	24,049
11/6/2020	Sell	33,300	$50.70	$1,688,310.00	11,779
11/4/2020	Sell	11,100	$50.29	$558,219.00	11,779
10/15/2020	Sell	11,100	$51.55	$572,205.00	11,779
9/23/2020	Sell	11,100	$48.16	$534,576.00	11,779
8/21/2020	Sell	33,300	$42.84	$1,426,572.00	11,779
7/17/2020	Sell	33,300	$39.58	$1,318,014.00	22,879
6/25/2020	Sell	11,100	$46.88	$520,368.00	11,779
6/23/2020	Sell	11,100	$46.85	$520,035.00	11,779
5/20/2020	Sell	31,372	$40.48	$1,269,938.56	32,051
5/18/2020	Sell	11,100	$39.32	$436,452.00	101,879
5/14/2020	Sell	31,200	$35.32	$1,101,984.00	101,879
4/22/2020	Sell	25,600	$30.28	$775,168.00	85,579
4/20/2020	Sell	14,900	$28.83	$429,567.00	85,579
1/17/2020	Sell	3,700	$27.96	$103,452.00	74,379
1/15/2020	Sell	3,700	$29.52	$109,224.00	74,379

Harlan S. Robins Buying and Selling Activity at Adaptive Biotechnologies

Adaptive Biotechnologies Company Overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Today's Range

Now: $6.39

$5.84

$6.51

50 Day Range

MA: $5.50

$4.40

$6.78

2 Week Range

Now: $6.39

$2.28

$7.07

Volume

1,566,760 shs

Average Volume

1,411,798 shs

Market Capitalization

$943.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis

From Stansberry Research | Ad

Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.

Click here to see Dan's full warning to the public.

Harlan Robins Biography and Net Worth

What is Harlan S. Robins' net worth?

How old is Harlan S. Robins?

What is Harlan S. Robins' salary?

How do I contact Harlan S. Robins?

Has Harlan S. Robins been buying or selling shares of Adaptive Biotechnologies?

Who are Adaptive Biotechnologies' active insiders?

Are insiders buying or selling shares of Adaptive Biotechnologies?